LOGObaidi.png LOGOlanglaikejidinggaopng.png

CN

Inflammatory

Createrna has several drugs for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, etc., and several projects have entered the clinical research stage.

  • Field

  • Program

  • Indications

  • PCC

  • IND

  • Phase I

  • Phase II

  • Phase III

  • NDA

  • info

Inflammatory

  • MY004

    RA/ Ps/ AD

  • MY009

    IBD

Inflammatory

Program:MY004

Indications:RA/ Ps/ AD

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ

Inflammatory

Program:MY009

Indications:IBD

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ

Respiratory System

Createrna has multiple projects in development for chronic cough and idiopathic pulmonary fibrosis (IPF), with some programs having already advanced to the clinical trial stage and IND submission phase.

  • Field

  • Program

  • Indications

  • PCC

  • IND

  • Phase I

  • Phase II

  • Phase III

  • NDA

  • info

Respiratory System

  • QR052

    RCC
    SAC

  • QR055

    IPF

  • QR056251

    IPF

  • QR056240

    IPF

  • QR057

    Cough

  • QR060

    Chronic Pain
    Cough

Respiratory System

Program:QR052

Indications:RCC
SAC

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ

Respiratory System

Program:QR055

Indications:IPF

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ


Respiratory System

Program:QR056251

Indications:IPF

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ


Respiratory System

Program:QR056240

Indications:IPF

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ


Respiratory System

Program:QR057

Indications:Cough

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ


Respiratory System

Program:QR060

Indications:Chronic Pain
Cough

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ


Kidney System

Createrna is advancing multiple programs in IgA nephropathy and other therapeutic indications.

  • Field

  • Program

  • Indications

  • PCC

  • IND

  • Phase I

  • Phase II

  • Phase III

  • NDA

  • info

Kidney System

  • MY008

    PNH/ IgAN

  • QR059

    PNH

  • MY004

    IgAN

Kidney System

Program:MY008

Indications:PNH/ IgAN

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ

Kidney System

Program:QR059

Indications:PNH

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ

Kidney System

Program:MY004

Indications:IgAN

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ

Cardiovascular System

Createrna's primary hypertension project is currently under development and has entered the Phase 3 clinical trial stage.

  • Field

  • Program

  • Indications

  • PCC

  • IND

  • Phase I

  • Phase II

  • Phase III

  • NDA

  • info

Cardiovascular System

  • QR12000（QR01019）

    PH

Cardiovascular System

Program:QR12000（QR01019）

Indications:PH

PCC

IND-Enabling

IND

Clinical Phase I

Clinical Phase Ⅱ

Clinical Phase Ⅲ